🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to health experts.

A Global Health Concern

The sexually transmitted infection are escalating globally, with data suggesting in excess of 82 million instances annually. Particularly high rates are observed in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts hope that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

According to findings published in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This places it at an equal footing with the existing first-line therapy, which combines an injection and a pill. The research involved hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have shared positive views. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for public health efforts. This is considered crucial to reduce the burden of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea globally.